DrugPatentWatch Database Preview
Alnylam Pharms Inc Company Profile
What is the competitive landscape for ALNYLAM PHARMS INC, and when can generic versions of ALNYLAM PHARMS INC drugs launch?
ALNYLAM PHARMS INC has one approved drug.
There are twenty-one US patents protecting ALNYLAM PHARMS INC drugs.
Summary for Alnylam Pharms Inc
| US Patents: | 21 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Alnylam Pharms Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alnylam Pharms Inc | ONPATTRO | patisiran sodium | SOLUTION;INTRAVENOUS | 210922-001 | Aug 10, 2018 | RX | Yes | Yes | 8,552,171 | ➤ Try a Free Trial | Y | Y | ➤ Try a Free Trial | ||
| Alnylam Pharms Inc | ONPATTRO | patisiran sodium | SOLUTION;INTRAVENOUS | 210922-001 | Aug 10, 2018 | RX | Yes | Yes | 8,492,359 | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Alnylam Pharms Inc | ONPATTRO | patisiran sodium | SOLUTION;INTRAVENOUS | 210922-001 | Aug 10, 2018 | RX | Yes | Yes | 9,193,753 | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Alnylam Pharms Inc | ONPATTRO | patisiran sodium | SOLUTION;INTRAVENOUS | 210922-001 | Aug 10, 2018 | RX | Yes | Yes | 8,058,069 | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Non-Orange Book US Patents for Alnylam Pharms Inc
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 8,632,997 | RNA sequence-specific mediators of RNA interference | ➤ Try a Free Trial |
| 8,993,745 | RNA interference mediating small RNA molecules | ➤ Try a Free Trial |
| 9,150,605 | Compositions comprising alternating 2'-modified nucleosides for use in gene modulation | ➤ Try a Free Trial |
| 8,742,092 | RNA sequence-specific mediators of RNA interference | ➤ Try a Free Trial |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Alnylam Pharms Inc Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2004043978 | ➤ Try a Free Trial |
| European Patent Office | 2348134 | ➤ Try a Free Trial |
| Japan | 2009284915 | ➤ Try a Free Trial |
| Hong Kong | 1128733 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.
